Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Fluor-Op

&times

Overview

What is Fluor-Op?

FLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1%, is a topical anti-inflammatory agent for ophthalmic use.

Chemical Name:

Contains:

Fluorometholone 0.1%

with: polyvinyl alcohol 1.4%; benzalkonium chloride 0.004%, edetate disodium; sodium chloride; sodium phosphate monobasic, monohydrate; sodium phosphate dibasic, anhydrous; polysorbate 80; sodium hydroxide to adjust the pH, and purified water.



What does Fluor-Op look like?



What are the available doses of Fluor-Op?

Sorry No records found.

What should I talk to my health care provider before I take Fluor-Op?

Sorry No records found

How should I use Fluor-Op?

Sorry No records found


What interacts with Fluor-Op?

Sorry No Records found


What are the warnings of Fluor-Op?

Sorry No Records found


What are the precautions of Fluor-Op?

Sorry No Records found


What are the side effects of Fluor-Op?

Sorry No records found


What should I look out for while using Fluor-Op?

FLUOR-OP suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. FLUOR-OP suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.

Acute purulent untreated infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Corticosteroids are not effective in mustard gas keratitis and Sjögren’s keratoconjunctivitis.


What might happen if I take too much Fluor-Op?

Sorry No Records found


How should I store and handle Fluor-Op?

FLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-BFLUOR-OP (fluorometholone ophthalmic suspension, USP) 0.1% is supplied in plastic dropper bottles in the following sizes:5 mL…………………………………………………………………………..NDC 58768-358-0510 mL…………………………………………………………………………NDC 58768-358-1015 mL…………………………………………………………………………NDC 58768-358-15Store at controlled room temperature .Protect from freezing. Shake well before using. Keep bottle tightly closed when not in use.Rx onlyMfd. by OMJ Pharmaceuticals, Inc., San Germán, P.R., 00683 for:Novartis OphthalmicsDuluth, GA 300976069-B


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A.

Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies on patients' eyes treated with both dexamethasone and fluorometholone 0.1% suspensions, fluorometholone demonstrated a lower propensity to increase intraocular pressure than did dexamethasone.

Non-Clinical Toxicology
FLUOR-OP suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. FLUOR-OP suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.

Acute purulent untreated infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Corticosteroids are not effective in mustard gas keratitis and Sjögren’s keratoconjunctivitis.

Lorazepam injection, like other injectable benzodiazepines, produces additive depression of the central nervous system when administered with other CNS depressants such as ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.

When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behavior has been observed.

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.

Marked sedation, excessive salivation, ataxia, and, rarely, death have been reported with the concomitant use of clozapine and lorazepam.

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with the concomitant use of haloperidol and lorazepam.

The risk of using lorazepam in combination with scopolamine, loxapine, clozapine, haloperidol, or other CNS-depressant drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of lorazepam and these drugs is required.

Concurrent administration of any of the following drugs with lorazepam had no effect on the pharmacokinetics of lorazepam: metoprolol, cimetidine, ranitidine, disulfiram, propranolol, metronidazole, and propoxyphene. No change in lorazepam dosage is necessary when concomitantly given with any of these drugs.

Lorazepam-Valproate Interaction

Concurrent administration of lorazepam (2 mg intravenously) with valproate (250 mg twice daily orally for 3 days) to 6 healthy male subjects resulted in decreased total clearance of lorazepam by 40% and decreased formation rate of lorazepam glucuronide by 55%, as compared with lorazepam administered alone. Accordingly, lorazepam plasma concentrations were about two-fold higher for at least 12 hours post- dose administration during valproate treatment. Lorazepam dosage should be reduced to 50% of the normal adult dose when this drug combination is prescribed in patients (see also).

Lorazepam-Oral Contraceptive Steroids Interaction

Coadministration of lorazepam (2 mg intravenously) with oral contraceptive steroids (norethindrone acetate, 1 mg, and ethinyl estradiol, 50 μg, for at least 6 months) to healthy females (n=7) was associated with a 55% decrease in half-life, a 50% increase in the volume of distribution, thereby resulting in an almost 3.7-fold increase in total clearance of lorazepam as compared with control healthy females (n=8). It may be necessary to increase the dose of lorazepam in female patients who are concomitantly taking oral contraceptives (see also).

Lorazepam-Probenecid Interaction

Concurrent administration of lorazepam (2 mg intravenously) with probenecid (500 mg orally every 6 hours) to 9 healthy volunteers resulted in a prolongation of lorazepam half-life by 130% and a decrease in its total clearance by 45%. No change in volume of distribution was noted during probenecid co-treatment. Lorazepam dosage needs to be reduced by 50% when coadministered with probenecid (see also).

The initial prescription and renewal of the medication order beyond 20 milliliters of FLUOR-OP suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.

As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.

If this product is used for 10 days or longer, intraocular pressure should be monitored (see WARNINGS).

Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.

Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical steroids.

Corticosteroid-containing preparations have also been reported to cause acute uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following use of corticosteroids.

The development of secondary ocular infection (bacterial, fungal and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (see WARNINGS).

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).